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EDITORIAL REVIEW
Anemia of end-stage renal disease (ESRD)
The association of anemia with both acute and chronic renal
failure has been recognized for over 100 years. It is a
hypoproliferative anemia with generally normocytic red cells
and is seen invariably when patients with ESRD become
symptomatic of uremia and require hemodialysis or peritoneal
dialysis. The association of anemia with the kidney is important
because this organ is responsible both for sensing oxygen
availability to tissues and for releasing erythropoietin (Ep) into
the circulation [1]. Under normal circumstances, a low level of
circulating Ep (10 to 30 milliunits/mi plasma) is capable of
maintaining a stable red cell mass [2]. Ep production, as
reflected by concentrations of the hormone in the urine and
plasma, may increase several-hundredfold in response to im-
paired oxygen delivery [1, 2]. Not surprisingly, then, Ep
production and the capacity of the kidney to respond to
impaired oxygen delivery are blunted when there is a decrease
in functional renal tissue. In general, the extent of renal
insufficiency in patients with ESRD is correlated directly with
the severity of anemia [3].
The anemia is important because it produces symptoms in
approximately one-half of the more than 200,000 patients on
dialysis world-wide and perhaps an equal number not yet
requiring dialysis. Only one-third of ESRD patients are reha-
bilitated by dialysis [4], the anemia being an important factor
contributing to fatigue and a sense of poor health.
Mechanisms of the anemia
The major mechanisms that have been recognized to contrib-
ute to the anemia of ESRD are a shortened red cell survival [5],
decreased Ep production (for the degree of anemia) [6], and
retained inhibitors or toxic metabolites in ESRD that inhibit
erythropoiesis [3, 7, 8]. Other recognized potential complica-
tions impairing marrow function are iron or folate deficiency [9,
10], aluminum toxicity [11—13], and the osteitis fibrosa associ-
ated with hyperparathyroidism [14].
Decreased red cell survival has been documented in ESRD
dialysis patients using isotope red cell tagging with 51Cr [15],
DF32P [16], '4C-cyanate [17], and measurements of carbon
monoxide exhalation [18]. The last technique, if properly con-
ducted, is extremely sensitive since the breakdown of one
molecule of heme releases one molecule of carbon monoxide.
In general, the hemolysis associated with ESRD is mild, with
red cell survival ranging from one-third normal to normal and
averaging approximately one-half normal [15—17]. The cause of
the shortened red cell survival appears to be extracellular since
the transfusion of normal red cells into uremic patients results
in a shortening of the survival of the transfused cells while
transfusion of red cells from patients with ESRD into non-
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uremic subjects is associated with normalization of red cell
survival [19]. Neither hemodialysis nor continuous ambulatory
peritoneal dialysis (CAPD) improves red cell survival [16, 20,
21]. In our opinion, hemolysis is not a major cause of anemia in
most patients since a normal erythroid marrow can compensate
easily for this degree of shortening of red cell survival. How-
ever, a subset of patients with ESRD develops chronic
hemolysis from hypersplenism with red cell survival of less than
one-fourth normal. These patients generally benefit from sple-
nectomy [22]. Acute hemolysis has been observed if a patient's
red cells are exposed during dialysis to various oxidants
[23—251, excessive formaldehyde in the dialysate [26], or over-
heated [27] or hypotonic dialysate [28]. This complication
should not occur with proper dialysis monitoring.
The most important cause of the anemia of ESRD is de-
creased Ep production. It has been known for over twenty
years that serum levels of Ep in patients with ESRD are well
below those of comparably anemic patients who have normal
renal function. What was not appreciated initially is that a
number of patients with ESRD have elevated levels of biolog-
ically active Ep, which can be demonstrated if large volumes of
plasma are concentrated. Caro et al concentrated plasma from
normal subjects and patients with ESRD approximately two-
hundredfold and assayed the plasma concentrates for Ep using
the polycythemic mouse bioassay. The patients with ESRD had
values well below the plasma Ep levels of patients with com-
parable degrees of anemia but without renal failure [29], and
most had values similar to normal subjects. However, approx-
imately 40% of patients with ESRD had elevated levels of
bioactive Ep. Thus, in these individuals, Ep deficiency was
relative. Unfortunately, quantitative studies of red cell produc-
tion in these patients were not carried out and it was not
possible to determine if increased erythropoiesis correlated
with the levels of plasma Ep.
More recently, the development of a reliable radio-
immunoassay (RIA) for Ep has revealed that some patients with
ESRD have elevated levels of immunoreactive Ep [3]. How-
ever, the usual correlation between the degree of anemia and
elevated levels of plasma Ep, as would be expected if renal
function were normal, is not seen [2]. These data cannot be
interpreted unambiguously because of the possibility that the
RIA is measuring immunoreactive, but not biologically active,
fragments of the Ep molecule. Consequently, normal or even
elevated levels of immunoreactive Ep in patients with ESRD
may be misleading.
In addition to decreased Ep production, inhibitors of
erythropoiesis have been postulated to be of significance in
patients with ESRD. In several cell systems, a uremic environ-
ment impairs cell proliferation, including the lymphocyte re-
sponse to mitogens [30], and in vitro erythropoiesis [31].
However, the evidence for inhibitors that may be contributing
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to the anemia of ESRD is both contradictory and controversial,
and the real role of inhibitors remains to be defined precisely.
There are several clinical settings that suggest strongly that
substances retained in ESRD interfere with erythroid marrow
function. The most convincing evidence was provided by Caro
who showed elevated levels of bioactive Ep in the plasma of a
number of patients with ESRD [291, This finding implies that the
marrow is unable to respond to the circulating Ep in these
individuals. Furthermore, a few patients placed on
hemodialysis [32] or switched to CAPD [331 have had a signif-
icant improvement in hemoglobin and hematocrit in the absence
of dramatic changes in plasma Ep levels, suggesting that an
inhibitor was removed by dialysis.
In contrast to these observations, there are several sugges-
tions why inhibitors, if present, are of little physiological
relevance. First, approximately 3% of dialysis patients normal-
ize their hematocrits spontaneously [34]. Second, those patients
who develop a hemolytic-uremic syndrome have high circulat-
ing Ep levels (measured by bioassay), may require dialysis, and
yet erythropoiesis typically is increased dramatically. Third,
bilateral nephrectomy in a stable patient maintained by
hemodialysis results in a decrease in effective erythropoiesis
and a fall in hematocrit [35]. This last finding would suggest that
even the low levels of Ep produced by the residual diseased
kidneys were capable of maintaining red cell production and
that the removal of this source of Ep resulted in further
impairment of erythropoiesis.
Part of the problem in defining the role of inhibitors in the
anemia of ESRD is the lack of appropriate control data that
would support the specificity of such inhibitors. For example,
early reports that parathyroid hormone might be responsible for
the inhibition of red cell production [36] could not be confirmed
when pure hormone or a synthetic peptide of a partial sequence
was tested in culture [371. When only partially purified parathy-
roid extract preparations were tested, inhibition of in vitro
hematopoiesis was not specific for red cells, and the extracts
inhibited in vitro granulopoiesis as well [37]. In concert with
this, McGonigle et al recently have reported a correlation
between parathyroid hormone levels, creatinine, and anemia in
a large group of patients with ESRD. When multivariate anal-
ysis was carried out, pärathyroid hormone levels failed to
correlate with the anemia [38].
Radtke et al have reported that the polyamine spermine might
contribute to the anemia of ESRD [39]. While this material
certainly appears to be inhibitory in vitro, Caro, Hickey, and
Erslev have provided preliminary evidence that this material, as
well, is not specific for erythropoiesis [40] and Spragg, Bentley,
and Coles have contested reports of elevated spermine levels in
the plasma of patients with ESRD [41]. Finally, Delwiche,
Eschbach, and Adamson have studied the effect of uremic
human sera on the in vitro growth of mouse granulocyte/mac-
rophage colony-forming cells, erythroid colony-forming cells,
and megakaryocytic colony-forming cells. Their results, while
confirming the presence of inhibitory substances in the sera of
patients with ESRD, failed to demonstrate specificity of the
inhibition and in vitro granulopoiesis, and megakaryopoiesis
were suppressed as well as erythropoiesis [42]. Since granulo-
cyte and platelet production usually are not impaired in patients
with ESRD, results of such inhibitor studies must be interpreted
cautiously. To demonstrate if such inhibitors are of physiologic
relevance, it will be necessary to correlate their presence with
the in vivo response of patients to Ep replacement therapy.
Other recognized contributors to the anemia of ESRD include
iron and folate deficiencies, osteitis fibrosa associated with
hyperparathyroidism, and aluminum toxicity. Iron deficiency is
prevalent particularly in non-transfused hemodialysis patients
because the small, repetitive blood losses associated with the
dialyzer may exceed the absorption of iron from the diet.
However, since iron absorption is normal and not impaired by
uremia [43, 44], iron supplementation should maintain iron
stores as long as blood loss from other body sites is not
excessive. Iron stores can now be evaluated easily and should
be monitored by serum ferritin determinations every 4 to 6
months [45] and either maintained or corrected by oral [46] or
parenteral iron administration. Since erythroid marrow function
is decreased in dialysis patients, the rate of marrow iron efflux
is reduced and, hence, iron stores must be decreased markedly
before erythroid function is impaired further. Therefore, iron
supplementation is rarely required until serum ferritin levels fall
below 30 ng/ml. Caution is advised in the use of parenteral iron
since anaphylactic reactions occur occasionally and the indis-
criminate administration of parenteral iron, without serum
ferritin monitoring, can lead to iron overload with tissue
siderosis. Such complications do not develop if oral iron is used
since the bowel mucosa will regulate iron absorption according
to the body's iron stores [45]. Iron overload, as defined by a
serum ferritin of greater than 300 nglml, is common in most
patients prior to the initiation of dialysis, unless there has been
excessive blood loss previously. This is because a significant
amount of body iron shifts from circulating red cells to the
reticuloendothelial system, as erythropoiesis decreases with
progressive renal disease. If parenteral iron administration,
either as iron dextran or in the form of blood transfusions,
exceeds the normal gastrointestinal mucosal iron and dialyzer
blood (iron) losses, then iron stores will increase. It is still
uncertain, however, whether severe iron overload results in
clinical problems in dialysis patients. In patients who do de-
velop iron overload, serum ferritin levels will fall as a result of
recurrent dialyzer blood losses if supplemental iron therapy is
discontinued. However, since many of these patients are trans-
fusion dependent, they will continue to be at risk from tissue
siderosis.
Folate deficiency may develop also in hemodialysis patients
who either restrict their protein intake (because folate dialysis
loss exceeds dietary intake) [10], or who require diphenylhy-
dantoin therapy. The presence of red cell macrocytosis suggests
folate deficiency, if iron overload is excluded [47]. Oral folic
acid therapy corrects or prevents this complication, however,
most dialysis patients ingest enough dietary folate to remain in
positive folate balance [48].
Osteitis fibrosa, a complication of hyperparathyroidism, may
reduce the erythroid marrow space and, thereby, the erythroid
cellular mass. Surgical [14] or medical [49] management may
reverse this complication. If marrow fibrosis becomes severe,
extramedullary hematopoiesis with splenomegaly may be seen.
This can lead to pancytopenia and increased red cell destruction
[50].
Aluminum toxicity is an extremely interesting and recently
noted complication of patients on hemodialysis. Not only does
aluminum toxicity result in dementia [51] and osteomalacia [52],
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Fig. 1. The correlation of serum Ep levels as measured by RIA in seven
normal and five anemic, uremic sheep. Anemia was induced in normal
sheep by phenyihydrazine and/or phlebotomy. (Reproduced from J Clin
Invest 74:434—441, 1984, with permission of the authors and publishers.)
Symbols are: •, normal; 0, anemic, uremic animals.
but it also results in microcytic red cells and accentuates the
anemia [11]. The osteomalacia appears to be reversed with
long-term deferoxamine therapy [52]. It is not clear at the
present time how aluminum induces microcytosis. Examination
of erythroid cells from the marrow of several patients with
aluminum-induced microcytosis, but with normal or elevated
iron stores, has disclosed absent or markedly reduced
sideroblasts, suggesting that aluminum in some way interferes
with the incorporation of iron into the erythroid cell for heme
synthesis. Of interest is the fact that the microcytosis reverses
quickly—within 1 or 2 months—following the institution of
weekly deferoxamine therapy. This occurs generally before
there is any improvement in the hematocrit. At present, the
magnitude, as well as the pathophysiology, of the toxic effects
of aluminum on the erythron remain to be determined, as does
the possibility that aluminum excess will interfere with
erythropoiesis if the marrow is stimulated by Ep.
Treatment and the future
To date, there has been no satisfactory treatment for the
anemia of ESRD. Only androgens have had any impact on the
anemia [53]; however, not all patients respond [54], the anemia
rarely is corrected, and side effects may be significant [55, 56].
Red cell transfusions have been the only sure way to correct the
symptoms of tissue hypoxia, but such therapy is only tran-
siently effective and transfusions increase the risk of exposure
to hepatitis or other infectious agents, transplant sensitization,
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Fig. 2. Correction of anemia in a uremic sheep by daily infusions of
Ep-rich plasma. The normal sheep hematocrit is 30 to 34. Polycythemia
was created by continued infusions. Each arrow represents 500 ml of
infused Ep-rich plasma. Abbreviation: WB, whole blood. (Reproduced
from J Clin Invest 74:434-441, 1984, with permission of the authors and
publishers.)
and iron overload. Erythroid marrow suppression may be
another effect of transfusion therapy, especially if multiple units
of red cells are infused at once [32]. Repeated transfusions thus
may make a patient transfusion dependent. Although there may
be only a relatively small amount of Ep produced by the
residual renal tissue, there is evidence that the usual Ep-
hematocrit feedback loop is intact [57]; this would explain the
marrow-suppressing effects of transfusions. Consequently,
while a liberal transfusion policy has been advocated to en-
hance the survival of renal transplants [58], caution is suggested
in view of these potential complications, and transfusions
should be reserved for those who clearly are symptomatic with
anemia or who are active candidates for a kidney transplant.
Fortunately, we are now on the verge of being able to
evaluate the effectiveness of Ep therapy in ESRD. Recently,
biotechnology firms have revealed that they have isolated the
human structural gene for Ep [59], the gene has been expressed,
and biologically active material from recombinant sources
should be available for testing in patients soon. This is a major
advance for a number of reasons, but is of particular importance
to patients with severe anemia and ESRD. Once animal and
human trials for safety and efficacy satisfy the governmental
regulatory agencies, recombinant Ep should be available for
therapy trials.
Will Ep be effective in these patients? This is of great interest
and concern, obviously. Recently, we have attempted to ad-
dress this question in a sheep model in which uremia was
produced by subtotal nephrectomy [60], Varying degrees of
uremia were induced and some animals required maintenance
hemodialysis; all had relative Ep deficiency (Fig. 1). When
these animals were treated with Ep-rich plasma, red cell pro-
duction increased, and the anemia was corrected in all (Fig. 2)
[61]. These results are encouraging, but the extent to which the
model resembles ESRD in humans remains to be seen. Never-
theless, if the results with the model are correct, we would
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anticipate that daily, or perhaps every-other-day, intravenous
doses of Ep will correct the anemia in ESRD. The minimum
amount of Ep required to maintain a normal red cell mass has
yet to be established, but may vary depending on the co-
existence of the complications mentioned earlier. Although Ep
replacement will add to the cost of the medical care of patients
with ESRD and anemia, at least some of the expense will be
offset by the elimination of transfusion requirements and andro-
gen therapy and a better rate of patient rehabilitation. Of
course, transfusion dependent dialysis patients will be the first
to be treated. What is less obvious, however, is the advantage
of treating patients who are not transfusion dependent, but who
have severe anemia with hematocrits in the 20 to 30% range.
Only through careful physiologic studies will it be possible to
determine the optimal red cell mass in such individuals.
The availability of large amounts of recombinant Ep that is
biologically active also presents investigators with the opportu-
nity to study kinetics of hormone clearance, alterations in the
physical state of Ep in the circulation of uremic or normal
humans, and to correlate in vitro studies of erythropoietic
inhibition with in vivo response. This last information will be
particularly relevant in validating the tests for inhibitors and in
predicting which patients might benefit from hormone replace-
ment therapy. It is possible that the anemia of ESRD may be an
endocrine deficiency state primarily, soon to be eliminated in
many patients by specific replacement therapy.
References
JOSEPH W. ESCHDACH
JOHN W. ADAMSON
Seattle, Washington
1. ADAMSON JW: The erythropoietin/hematocrit relationship in nor-
mal and polycythemic man: implications for marrow regulation.
Blood 32:597—609, 1968
2. GARCIA JF, EBBE SN, HOLLANDER L, CUTTING HO, MILLER ME,
CRONKITE EP: Radioimmunoassay of erythropoietin: Circulating
levels in normal and polycythemic human beings. J Lab C/in Med
99:624—635, 1982
3. MCGONIGLE RJS, WALLIN JD, SHADDUCK RK, FISHER JW:
Erythropoietin deficiency and inhibition of erythropoiesis in renal
insufficiency. Kidney mt 25:437—444, 1984
4. GUTMAN RA, STEAD WW, ROBINSON RR: Physical activity and
employment status of patients on maintenance dialysis. N Eng J
Med 304:309—313, 1981
5. SHAw AR: Haemolysis in chronic renal failure. Br Med J
2:213—215, 1967
6. ADAMSON JW, ESCHBACH JW, FINCH CA: The kidney and
erythropoiesis. Am J Med 44:725—733, 1968
7. MCDERMOTT TF, GALBRAITH AJ, CORLETT RJ: Inhibition of cell
proliferation in renal failure and its significance to the uraemic
syndrome: a review. Scott Med J 20:317—327, 1975
8. WALLNER SF, VAUTRIN RM: Evidence that inhibition of
erythropoiesis is important in the anemia of chronic renal failure. J
Lab Clin Med 97:170—178, 1981
9. STRICKLAND ID, CHAPUT DE SAINTONGE DM, BOULTON FE,
FRANCIS B, ROUBIKOVA J, WATERS JI: The therapeutic equivalence
of oral and intravenous iron in renal dialysis patients. C/in Nephrol
7:55—57, 1977
10. HAMPERS CL, STREIFF R, NATHAN DG, SNYDER D, MERRILL JP:
Megaloblastic hematopoiesis in uremia and in patients on long-term
hemodialysis. N Eng J Med 276:551—554, 1967
11. SHORT AIK, WINNEY Ri, ROBSON JS: Reversible microcytic
hypochromic anaemia in dialysis patients due to aluminum intoxi-
cation. Proc Ear Dial Transplant Assoc 17:226—233, 1980
12. TOUAM M, MARTINEZ F, LACOUR B, BOURDON R, ZINGRAFF J,
DIGIuLI0 S, DRUEKE T: Aluminum-induced, reversible microcytic
anemia in chronic renal failure: clinical and experimental studies.
Clin Nephrol 19:295—298, 1983
13. WILLS MR, SAVORY J: Aluminum poisoning: Dialysis encephalop-
athy, osteomalacia, and anaemia. Lancet 1:29—34, 1983
14. BAROUR GL: Effect of parathyroidectomy on anemia in chronic
renal failure. Arch Intern Med 139:889—891, 1979
15. KOCK KM, PATYNA WD, SHALDON S, WERNER E: Anemia of the
regular hemodialysis patients and its treatment. Nephron
12:405-419, 1974
16. ESCHBACH JW, FUNK D, ADAMSON J, KUHN I, SCRIBNER BH,
FINCH CA: Erythropoiesis in patients with renal failure undergoing
chronic dialysis. N Eng J Med 276:653—658, 1967
17. ESCHBACH JW, KORN D, FINCH CA: '4C cyanate as a tag for red
cell survival in normal and uremic man. fLab C/in Med 89:823—828,
1977
18. LERNER R, WERNER B, ASABA H, TERNSTEDT B, ELMQUIST E:
Assessment of hemolysis in regular hemodialysis patients by mea-
suring carbon monoxide production rate. C/in Nephrol 20:239—243,
1983
19. JOSKE RA, MCALISTER JM, PRANKERD TAJ: Isotope investigations
of red cell production and destruction in chronic renal disease. C/in
Sci 15:511—522, 1956
20. BLUMBERG A, JARTI HR: Red cell metabolism and haemolysis in
patients on dialysis. Proc Eur Dial Transplant Assoc 9:91—95, 1972
21. HEFTI JE, BLUMBERG A, MARTI HR: Red cell survival and red cell
enzymes in patients on continuous peritoneal dialysis (CAPD). C/in
Nephro/ 19:232—235, 1983
22. A5ABA H, BERGSTROM J, LUNDGREN G, Soio B, TRANAEUS A,
ZACHRISSON L: Hypersequestration of 5Cr-labeled erythrocytes as
a criterion for splenectomy in regular hemodialysis patients. C/in
Nephro/ 8:304—307, 1977
23. MANZLER AD, SCHREINER AW: Copper-induced acute hemolytic
anemia. A new complication of hemodialysis. Ann Intern Med
73:409—412, 1970
24. NEILAN BA, EHLERS SM, KOLPIN CF, EATON JW: Prevention of
chloramine-induced hemolysis in dialyzed patients. C/in Nephro/
10: 105—108, 1975
25. CARLSON DJ, SHAPIRO FL: Methemoglobinemia from well water
nitrates: A complication of home dialysis. Ann Intern Med
73:757—759, 1970
26. ORRINGER EP, MATTERN WDL: Formaldehyde-induced hemolysis
during chronic hemodialysis. N Eng J Med 294:1416—1420, 1976
27. BERKES SL, KAHN SI, CHAZAN JA, GARELLA S: Prolonged
hemolysis from overheated dialysate. Ann Intern Med 83:363—364,
1975
28. SAID R, QUINTANILLA A, LEVIN N, IVANOVICH P: Acute
hemolysis due to profound hypo-osmolality. A complication of
hemodialysis. J Dial 1:447-452, 1977
29. CARO J, BROWN 5, MILLER 0, MURRAY T, ERSLEV AJ:
Erythropoietin levels in uremic nephric and anephric patients. J
Lab C/in Med 93:449—458, 1979
30. KASAKURA S, LOWENSTEIN L: The effect of uremic blood on mixed
leukocyte reaction and cultures of leukocytes with PHA. Trans-
plantation 2:283—290, 1967
31. FISHER JW: Mechanism of anemia of chronic renal failure. Editorial
review. Nephron 25:106—111, 1980
32. ESCHBACH JW, ADAMSON JW, COOK JD: Disorders of red blood
cell production in uremia. Arch lntern Med 126:812—815, 1970
33. ZAPPACOSTA AR, CARO J, ERSLEV A: Normalization of hematocrit
in patients with end-stage renal disease on continuous ambulatory
peritoneal dialysis. Am J Med 72:53—57, 1982
34. CHARLES G, LUNDIN AP III, DELANO BG, BROWN C, FRIEDMAN
BA: Absence of anemia in maintenance hemodialysis. Int J Artf
Organs 4:277—279, 1981
35. KOMINAMI N, LOWRIE EG, IANHEZ LE, SKAREN A, HAMPERS CL,
MERRILL JP, LANGE RD: The effect of total nephrectomy on
hematopoiesis in patients undergoing chronic hemodialysis. J Lab
C/in Med 78:524—532, 1971
36. MEYTES D, BOGIN E, MA A, DUKES PP, MASSRY SG: Effect of
parathyroid hormone on erythropoiesis. J Gun Invest 67:1263—1269,
1981
37. DELWICHE F, GARRITY MJ, POWELL JS, ROBERTSON RP,
Anemia of end-stage renal disease 5
ADAMSON JW: High levels of the circulating form of parathyroid
hormone do not inhibit in vitro erythropoiesis. J Lab Clin Med
102:613—620, 1983
38. MCGONIGLE RJS, WALLIN JD, HUSSERL F, DEFTOS U, RICE JC,
O'NEILL WH, FISHER JW: Potential role of parathyroid hormone
as an inhibitor of erythropoiesis in the animal of renal failure. J Lab
Clln Med 104:1016—1026, 1984
39. RADTKE HW, REGE AB, LAMARCHE MB, BARTOS D, BARTOS F,
CAMPBELL RA, FISHER JW: Identification of spermine as an
inhibitor of erythropoiesis in patients with chronic renal failure. J
Clin Invest 67: 1623—1629, 1981
40. CARO J, HICKEY J, ERSLEV AJ: Is spermine the uremic
erythropoietic inhibitor (abstract)? Gun Res 31:309A, 1983
41. SPRAGG BP, BENTLEY DP, COLES GA: Anaemia of chronic renal
failure. Polyamines are not raised in uraemic serum. Nephron
38:65—66, 1984
42. DELWICHE F, ESCHBACH JW, ADAMSON JW: The anemia of
chronic renal failure (CRF): lack of in vitro specificity of serum
inhibitors (abstract). Blood 62:45A, 1983
43. ESCHBACH JW, CooK JD, FINCH CA: Iron absorption in chronic
renal disease. Clin Sci 38:191—201, 1970
44. MILMAN N: Iron absorption measured by whole body counting and
the relation to marrow iron stores in chronic uremia. Clin Neph
17:77—81, 1972
45. ESCHBACH JW, Cook JD, SCRIBNER BH, FINCH CA: Iron balance
in hemodialysis patients. Ann Intern Med 87:710—713, 1977
46. PARKER PA, IZARD MW, MAHER IF: Therapy of iron deficiency
anemia in patients on maintenance dialysis. Nephron 23:181—186,
1979
47. GOKAL R, WEATHERALL DJ, BUNCH C: Iron induced increase in
red cell size in haemodialysis patients. Q JMed 48:393—401, 1979
48. CUNNINGHAM J, SHARMAN VL, GOODWIN FJ, MARSH FP: Do
patients receiving haemodialysis need folic acid supplements (let-
ter)? Br MedJ 282:1582, 1981
49. ZINGRAFF J, DRUEKE T, MARIE P, MAN NK, JLJNGERS P. BORDIER
P: Anemia and secondary hyperparathyroidism. Arch Intern Med
138: 1650-1652, 1978
50. WEINBERG SG, LUBIN A, WIENER S, DEois MP, GHOSE MK,
KOPELMAN RC: Myelofibrosis and renal osteodystrophy. Am J
Med 63:755—764, 1977
51. ALFREY AC: Aluminum intoxication. Editorial review. N Eng J
Med 310:1113—1114, 1984
52. BROWN DJ, HAM KN, DAWBORN JK, XIPELL JM: Treatment of
dialysis osteomalacia with desferrioxamine. Lancet 11:343—345,
1982
53. ESCHBACH JW, ADAMSONJW: Improvement in the anemia of
chronic renal failure with fluoxymesterone. Ann intern Med
78:527—534, 1973
54. NEFF MS, GOLDBERG J, SLIFKIN RF, EISER AR, CALAMIA V,
KAPLAN M, BAEZ A, GUPTA S, MArroO N: A comparison of
androgens for anemia in patients on hemodialysis. N Eng J Med
304:871—875, 1981
55. Editorial. Androgens in the anaemia of chronic renal failure. Br
Med J 2:417—418, 1977
56. AHMAD 5, GOODMAN W, PAGEL M, SHEN F: Accelerated creati-
nine generation and elevated CPK due to androgens. Proc Clin Dial
TransplantForum 10:174—176, 1980
57. RADTKE HW, CLAUSSNER A, ERBES PM, SCHEUERMANN EH,
SCHOEPPE W, KOCH KM: Serum erythropoietin concentration in
chronic renal failure: relationship to degree of anemia and excre-
tory renal function. Blood 54:877—884, 1979
58. VINCENTI F, DUCA RM, AMEND W, PERKINS HA, COCHRUM KC,
FEDUSKA NJ, SALVATIERRA 0 JR: Immunologic factors determin-
ing survival of cadaver-kidney transplants. N Eng J Med
299:793—798, 1978
59. JACOBS K, SHOEMAKER C, RUDERSDORF R, NEILL SD, KAUFMAN
Ri, MUFSON A, SEEHRA J, JONES SS, HEWICK R, FRITCH EF,
KAWAKITA M, SHIMIzu T, MIYAKE T: Isolation and characteriza-
tion of genomic and cDNA clones of human erythropoietin. Nature
313:808—810, 1985
60. ESCHBACH JW, ADAMSON JW, DENNIS MB: Physiologic studies in
normal and uremic sheep: I. The experimental model. Kidney mt
18:725—731, 1980
61. ESCHBACH JW, MLADENOVIC I, GARCIA JF, WAHL PW, ADAMSON
JW: The anemia of chronic renal failure in sheep. Response to
erythropoietin-rich plasma in vivo. J Clin Invest 74:434—441, 1984
